港股異動 | 螞蟻金服概念股繼續走強 中國動向(3818.HK)大漲超11%
格隆匯8月26日丨螞蟻金服概念股繼續走強,中國動向(3818.HK)大漲超11%,阿里巴巴漲超3%創新高,騰訊漲超1%帶動恆指漲逾40點。昨晚螞蟻集團向上交所及港交所同步遞交上市招股書,擬在A+H發行的新股數量合計不低於發行後總股本的10%,發行後總股本不低於300.3897億股(綠鞋前)。本次A股發行可引入綠鞋機制,超額配售權最高不超過15%。富瑞曾發研報指,由於阿里巴巴擁有螞蟻集團33%股權,故螞蟻集團估值的潛在上漲空間將進一步推動阿里巴巴的估值。重申阿里巴巴為該行業的首選,維持買入評級,目標價為307港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.